(VIANEWS) – SM Energy Company (SM), Neurocrine Biosciences (NBIX), Harmony Biosciences Holdings (HRMY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SM Energy Company (SM)
44.8% sales growth and 22.71% return on equity
SM Energy Company, an independent energy company, engages in the acquisition, exploration, development, and production of oil, gas, and natural gas liquids in the state of Texas. It has working interests in oil and gas producing wells in the Midland Basin and South Texas. The company was formerly known as St. Mary Land & Exploration Company and changed its name to SM Energy Company in May 2010. SM Energy Company was founded in 1908 and is headquartered in Denver, Colorado.
Earnings Per Share
As for profitability, SM Energy Company has a trailing twelve months EPS of $6.92.
PE Ratio
SM Energy Company has a trailing twelve months price to earnings ratio of 6.06. Meaning, the purchaser of the share is investing $6.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.71%.
Moving Average
SM Energy Company’s worth is below its 50-day moving average of $42.72 and below its 200-day moving average of $44.17.
2. Neurocrine Biosciences (NBIX)
20.8% sales growth and 15.55% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $3.32.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 33.78. Meaning, the purchaser of the share is investing $33.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.55%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.4%, now sitting on 2.12B for the twelve trailing months.
Moving Average
Neurocrine Biosciences’s worth is way below its 50-day moving average of $131.99 and way below its 200-day moving average of $136.04.
3. Harmony Biosciences Holdings (HRMY)
17.6% sales growth and 22.46% return on equity
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Earnings Per Share
As for profitability, Harmony Biosciences Holdings has a trailing twelve months EPS of $1.95.
PE Ratio
Harmony Biosciences Holdings has a trailing twelve months price to earnings ratio of 19.39. Meaning, the purchaser of the share is investing $19.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.46%.
4. Liberty Media Corporation (FWONK)
11.4% sales growth and 4.13% return on equity
Formula One Group engages in the motorsports business. It holds commercial rights for the world championship, approximately a nine-month long motor race-based competition in which teams compete for the constructors' championship and drivers compete for the drivers' championship. The company was founded in 1950 and is based in Englewood, Colorado. Formula One Group is a subsidiary of Liberty Media Corporation.
Earnings Per Share
As for profitability, Liberty Media Corporation has a trailing twelve months EPS of $1.07.
PE Ratio
Liberty Media Corporation has a trailing twelve months price to earnings ratio of 72.38. Meaning, the purchaser of the share is investing $72.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.13%.
Volume
Today’s last reported volume for Liberty Media Corporation is 786382 which is 39.26% below its average volume of 1294860.
Yearly Top and Bottom Value
Liberty Media Corporation’s stock is valued at $77.45 at 06:22 EST, below its 52-week high of $82.23 and way higher than its 52-week low of $60.95.
5. Atlanticus Holdings Corporation (ATLC)
10.6% sales growth and 18.86% return on equity
Atlanticus Holdings Corporation provides credit and related financial services and products to customers the United States. It operates in two segments, Credit as a Service, and Auto Finance. The Credit as a Service segment originates a range of consumer loan products, such as private label and general purpose credit cards originated by lenders through various channels, including retail and healthcare, direct mail solicitation, digital marketing, and partnerships with third parties; and offers credit to their customers for the purchase of various goods and services, including consumer electronics, furniture, elective medical procedures, healthcare, educational services, and home-improvements by partnering with retailers and service providers. In addition, it offers loan servicing, such as risk management and customer service outsourcing for third parties; and engages in testing and investment activities in consumer finance technology platforms. The Auto Finance segment purchases and/or services loans secured by automobiles from or for a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here, and used car business. This segment also provides floor plan financing and installment lending products. Further, the company invests in and services portfolios of credit card receivables. Atlanticus Holdings Corporation was founded in 1996 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Atlanticus Holdings Corporation has a trailing twelve months EPS of $4.21.
PE Ratio
Atlanticus Holdings Corporation has a trailing twelve months price to earnings ratio of 8.29. Meaning, the purchaser of the share is investing $8.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.86%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.5%, now sitting on 362.25M for the twelve trailing months.
Sales Growth
Atlanticus Holdings Corporation’s sales growth is 10.8% for the ongoing quarter and 10.6% for the next.
6. Option Care Health (OPCH)
10.5% sales growth and 14.64% return on equity
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and others; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Earnings Per Share
As for profitability, Option Care Health has a trailing twelve months EPS of $1.2.
PE Ratio
Option Care Health has a trailing twelve months price to earnings ratio of 25.97. Meaning, the purchaser of the share is investing $25.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.64%.
